[go: up one dir, main page]

NO944838D0 - Arabinogalactan derivatives and uses thereof - Google Patents

Arabinogalactan derivatives and uses thereof

Info

Publication number
NO944838D0
NO944838D0 NO944838A NO944838A NO944838D0 NO 944838 D0 NO944838 D0 NO 944838D0 NO 944838 A NO944838 A NO 944838A NO 944838 A NO944838 A NO 944838A NO 944838 D0 NO944838 D0 NO 944838D0
Authority
NO
Norway
Prior art keywords
arabinogalactan derivatives
arabinogalactan
derivatives
Prior art date
Application number
NO944838A
Other languages
Norwegian (no)
Other versions
NO944838L (en
Inventor
Chu Jung
Philip Enriques
Stephen Palmacci
Lee Josephson
Original Assignee
Advanced Magnetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Magnetics Inc filed Critical Advanced Magnetics Inc
Publication of NO944838D0 publication Critical patent/NO944838D0/en
Publication of NO944838L publication Critical patent/NO944838L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/605—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the macromolecule containing phosphorus in the main chain, e.g. poly-phosphazene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
NO944838A 1992-06-17 1994-12-14 Arabinogalactan derivatives and uses thereof NO944838L (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1992/005091 WO1993025239A1 (en) 1992-06-17 1992-06-17 Arabinogalactan derivatives and uses thereof

Publications (2)

Publication Number Publication Date
NO944838D0 true NO944838D0 (en) 1994-12-14
NO944838L NO944838L (en) 1995-02-17

Family

ID=4154623

Family Applications (1)

Application Number Title Priority Date Filing Date
NO944838A NO944838L (en) 1992-06-17 1994-12-14 Arabinogalactan derivatives and uses thereof

Country Status (5)

Country Link
EP (1) EP0646018A1 (en)
JP (1) JPH07507794A (en)
CA (1) CA2135295A1 (en)
NO (1) NO944838L (en)
WO (1) WO1993025239A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5490991A (en) * 1986-07-03 1996-02-13 Advanced Magnetics, Inc. Directed delivery of radioprotectants using a receptor specific carrier
US5554386A (en) * 1986-07-03 1996-09-10 Advanced Magnetics, Inc. Delivery of therapeutic agents to receptors using polysaccharides
US5728518A (en) * 1994-01-12 1998-03-17 The Immune Response Corporation Antiviral poly-and oligonucleotides
FR2716625B1 (en) * 1994-02-25 1996-04-26 Gouchet Franck Arno Preparation and use of pharmaceutical and cosmetic forms containing inclusion compounds with cysteamine cyclodextrins, cysteamine salts, or cysteamine derivatives, in salt form or not.
US5567685A (en) * 1994-08-16 1996-10-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Water-Soluble polyene conjugate
US5897987A (en) 1996-03-25 1999-04-27 Advanced Reproduction Technologies, Inc. Use of arabinogalactan in cell cryopreservation media
US6303584B1 (en) 1996-11-20 2001-10-16 The University Of Montana Water soluble lipidated arabinogalactan
US6011008A (en) * 1997-01-08 2000-01-04 Yissum Research Developement Company Of The Hebrew University Of Jerusalem Conjugates of biologically active substances
CA2280997C (en) 1997-03-11 2013-05-28 Perry B. Hackett Dna-based transposon system for the introduction of nucleic acid into dna of a cell
US6929936B1 (en) * 1997-07-18 2005-08-16 Danisco A/S Composition comprising an enzyme having galactose oxidase activity and use thereof
JP4873513B2 (en) * 1998-04-27 2012-02-08 ロンザ，インコーポレイティド Arabinogalactan derivatives and compositions containing them
US7160682B2 (en) 1998-11-13 2007-01-09 Regents Of The University Of Minnesota Nucleic acid transfer vector for the introduction of nucleic acid into the DNA of a cell
IL131074A0 (en) * 1999-07-23 2001-03-19 Polygene Ltd A biodegradable polycation composition for delivery of an anionic macromolecule
EP1286699A2 (en) * 2000-05-19 2003-03-05 Regents Of The University Of Minnesota Composition for delivery of compounds to cells
US8227432B2 (en) 2002-04-22 2012-07-24 Regents Of The University Of Minnesota Transposon system and methods of use
ITMI20040928A1 (en) 2004-05-07 2004-08-07 Uni Di Bologna Dipartiment O D PROCEDURE FOR THE PREPARATION OF DOXORUBICIN CONJUGATES WITH LACTOSAMINATED HUMAN ALBUMIN
ITMI20051743A1 (en) * 2005-09-20 2007-03-21 Uni Di Bologna Dipartimento Di Patologia Spa USE OF DOXORUBICINE CONJUGIES WITH LATTOSAMINATED ALBUMIN
RU2359975C2 (en) * 2007-04-04 2009-06-27 Институт нефтехимии и катализа РАН Method for production of modified arabinogalactan
CN102399238B (en) * 2011-12-21 2013-06-12 开封明仁药业有限公司 Preparation method for amifostine
RU2521649C1 (en) * 2013-03-04 2014-07-10 Федеральное Государственное Бюджетное Учреждение Науки Институт Химии И Химической Технологии Сибирского Отделения Российской Академии Наук (Иххт Со Ран) Method of producing sulphated arabinogalactan derivatives
US10994013B2 (en) 2013-04-24 2021-05-04 Temple University—Of the Commonwealth System of Higher Education Solid dosage form containing arabinogalactan

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3250023T (en) * 1981-01-14 1990-03-29
JPH0816118B2 (en) * 1988-02-03 1996-02-21 呉羽化学工業株式会社 Antiviral agent
JPH04501218A (en) * 1988-08-04 1992-03-05 アドヴァンスド　マグネティックス　インコーポレーティッド Receptor-mediated endocyto-cis MRI contrast agent

Also Published As

Publication number Publication date
CA2135295A1 (en) 1993-12-23
JPH07507794A (en) 1995-08-31
EP0646018A1 (en) 1995-04-05
NO944838L (en) 1995-02-17
WO1993025239A1 (en) 1993-12-23

Similar Documents

Publication Publication Date Title
NO961425D0 (en) 1N-alkyl-N-arylpyrimidinamines and derivatives thereof
DE59208263D1 (en) 3-aryl-4-hydroxy-delta3-dihydrofuranone and 3-aryl-4-hydroxy-delta3-dihydrothiophenone derivatives
FI961939A7 (en) Antithrombotic amidinophenylalanine and amidinopyridylalanine derivatives
FI961599A7 (en) 1N-Alkyl-N-arylpyrimidineamines and their derivatives
NO944838D0 (en) Arabinogalactan derivatives and uses thereof
ITMI920408A1 (en) BENZOPYRANIC AND BENZOTHIOPYRANIC DERIVATIVES
BR1100824A (en) Pharmaceutical composition and composition
NO922291D0 (en) 7-AZAISOINDOLINYL-QUINOLON AND NAVYTHYRIDONCARBOXYLIC ACID DERIVATIVES
FI930208L (en) QUINAZOLE DERIVATIVES
ATA75293A (en) INDOLDER DERIVATIVES
FI933037A7 (en) THIAZOLOLYLPHENYL DERIVATIVES
IT1266582B1 (en) (DI) AZACYLO-HEXANIC AND DIAZACYLO-HEPTANIC DERIVATIVES
NO943763D0 (en) 4-arylamino-benzopyrans and related compounds
FI934004A7 (en) 7-isoindolinylquinolone and naphthyridone derivatives
DE69330497D1 (en) CHINAZOLIN DERIVATIVES
FI20010214L (en) Acylaminoindole derivatives
DE59308714D1 (en) CYCLOBUTANE-BENZENE DERIVATIVES
FI20002460A7 (en) 4-diphenylmethylpiperidine derivatives
FI933201L (en) VAERME AND KYLVAL
NO922934D0 (en) CYCLE-HEXAN AND TETRA-HYDROPYRANDER DERIVATIVES
DK0821692T3 (en) Immunopotensing inosine monophosphate-5'-nucleotidase-resistant derivatives and uses thereof
DE69313890D1 (en) 5-aminoflavone derivatives
FI933019L (en) BENZOTIAZEPIN AND BENZOXATZEPINDERIVAT
IS1813B (en) Use of ferrozene and / or ferrozene derivatives
FI930367L (en) PURIDINE DERIVATIVES